Daniel Flynn
Founder at Deciphera Pharmaceuticals LLC
Net worth: 5 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Hoerter | M | 53 |
Deciphera Pharmaceuticals LLC
 Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 6 years |
| Franklin Friedman | M | 66 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.
University of Kansas
| 10 years |
| Ron Squarer | M | 57 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 5 years |
| James Bristol | M | 77 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 17 years |
| John Martin | M | 63 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 9 years |
| Susan Kelley | M | 69 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 5 years |
| Patricia Allen | F | 62 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 8 years |
| Dennis Walsh | M | 56 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 9 years |
| Edward Benz | M | 78 | 5 years | |
| Tucker Kelly | M | 53 | 9 years | |
| Rajesh Devraj | M | - | 13 years | |
| Jama Pitman | M | 45 | 9 years | |
| Matthew Sherman | M | 68 | 5 years | |
| Lisa Amaya Price | F | - | 2 years | |
| Kelley Dealhoy | F | - | 2 years | |
| Daniel Martin | M | 49 | 6 years | |
| Rodrigo Ruiz Soto | M | - | 7 years | |
| Dashyant Dhanak | M | 63 | 1 years | |
| Jeff Held | M | 55 | 6 years | |
| Kevin Brodbeck | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Taylor | M | 69 | 7 years | |
| Nicholas J. Kovich | M | - |
University of Kansas
| 7 years |
| Liam Ratcliffe | M | 60 | 2 years | |
| Rich Jones | M | 69 |
University of Kansas
| 5 years |
| Loren Moll | M | 67 |
University of Kansas
| 7 years |
| Kevin Rauckman | M | 62 |
University of Kansas
| 6 years |
| Dave L. Anderson | M | - |
University of Kansas
| 7 years |
| Michael Ross | M | 75 | 4 years | |
| Jay Meschke | M | - |
University of Kansas
| 5 years |
| Susan Mussell | F | - |
University of Kansas
| 4 years |
| Brent Flanders | M | - |
University of Kansas
| 4 years |
| Shailendra Singh | M | - |
University of Kansas
| 2 years |
| David J. Ricketts-Kingfisher | M | - |
University of Kansas
| 4 years |
| Laurie Kirby | F | - |
University of Kansas
| 4 years |
| Mark D. Hinderks | M | - |
University of Kansas
| 4 years |
| Jamal H. A. Nahhas | M | - |
University of Kansas
| 4 years |
| Jay Ketterling | M | - |
University of Kansas
| 2 years |
| Mark Thomas | M | - |
University of Kansas
| 4 years |
| Robert M. Barnes | M | - |
University of Kansas
| 4 years |
| Steve Merdinger | M | - |
University of Kansas
| 4 years |
| Thomas Cohen | M | - |
University of Kansas
| 4 years |
| William H. Colby | M | - |
University of Kansas
| 3 years |
| Joseph Dullea | M | - |
University of Kansas
| 4 years |
| Fred Stattman | M | - |
University of Kansas
| 4 years |
| Robert Steven Kaplan | M | 65 |
University of Kansas
| 4 years |
| Steven C. Miller | M | - |
University of Kansas
| 3 years |
| Mark Henke | M | - |
University of Kansas
| 3 years |
| Lesa Mitchell | F | - |
University of Kansas
| 4 years |
| Curtis Rosebraugh | M | 66 |
University of Kansas
| 4 years |
| Robert Anderson | M | - |
University of Kansas
| 4 years |
| Oliver Rosen | M | 59 | 4 years | |
| Shawn Del Monaghan | M | - |
University of Kansas
| 4 years |
| Scott Wren | M | - |
University of Kansas
| 4 years |
| Brian Eric Thompson | M | - |
University of Kansas
| 4 years |
| Dale Boger | M | - |
University of Kansas
| 6 years |
| Brad Sanders | M | 66 |
University of Kansas
| 4 years |
| William H. Katherman | M | 65 |
University of Kansas
| 4 years |
| Doug Degn | M | - |
University of Kansas
| 4 years |
| Brett Reber | M | 64 |
University of Kansas
| 4 years |
| Rebecca P. F. MacDonald | M | - |
University of Kansas
| 3 years |
| William F. Graveman | M | - |
University of Kansas
| 4 years |
| Zulkipli bin Mat Noor | M | 74 |
University of Kansas
| 4 years |
| Richard J. Reischman | M | - |
University of Kansas
| 4 years |
| Paul J. Blotkamp | M | - |
University of Kansas
| 1 years |
| Michael L. Bengtson | M | - |
University of Kansas
| 4 years |
| Brian Nelson Kaufman | M | - |
University of Kansas
| 4 years |
| Quinten L. Nufer | M | - |
University of Kansas
| 4 years |
| David Jenkins | M | 67 |
University of Kansas
| 4 years |
| John J. Holland | M | 74 |
University of Kansas
| 2 years |
| Troy D. Cook | M | 61 |
University of Kansas
| 4 years |
| Kim Scott | F | - |
University of Kansas
| 4 years |
| John C. Nettels | M | 67 |
University of Kansas
| 4 years |
| John M. Welch | M | - |
University of Kansas
| 4 years |
| Steve Dixon | M | 65 |
University of Kansas
| 4 years |
| Archie Dykes | M | 93 |
University of Kansas
| 7 years |
| John Edward Hayes | M | 61 |
University of Kansas
| 4 years |
| Cynthia Carroll | F | 67 |
University of Kansas
| 1 years |
| John W. Poyhonen | M | 64 |
University of Kansas
| 4 years |
| James J. Ludwig | M | 65 |
University of Kansas
| 4 years |
| Susan Spradley | F | 63 |
University of Kansas
| 4 years |
| Garry Tanner | M | - |
University of Kansas
| 4 years |
| Steven L. Rist | M | - |
University of Kansas
| 3 years |
| Peter Brown | M | 65 |
University of Kansas
| 2 years |
| Tom D. Taylor | M | - |
University of Kansas
| 4 years |
| Cyndi Roth | F | - |
University of Kansas
| 4 years |
| Karen L. Cooper | F | - |
University of Kansas
| 4 years |
| Brad Burnside | M | - |
University of Kansas
| 1 years |
| Stephen J. Gish | M | - |
University of Kansas
| 4 years |
| Charlie Himmelberg | M | - |
University of Kansas
| 4 years |
| James S. Swenson | M | - |
University of Kansas
| 4 years |
| Christopher J. Morl | M | 65 | 4 years | |
| Marc A. Messner | M | 62 |
University of Kansas
| 4 years |
| Julie Baumann | F | - |
University of Kansas
| 4 years |
| Ajit J. Deora | M | 67 |
University of Kansas
| 2 years |
| Michael R. Block | M | - |
University of Kansas
| 4 years |
| Michael J. Regier | M | - |
University of Kansas
| 4 years |
| Hale D. Ritchie | M | - |
University of Kansas
| 4 years |
| Susan Morgenstern | F | - |
University of Kansas
| 4 years |
| Anand Chand Burman | M | 72 |
University of Kansas
| 3 years |
| Gregory Mosier | M | - |
University of Kansas
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel Flynn
- Personal Network